{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05271630",
            "orgStudyIdInfo": {
                "id": "MCC-20816"
            },
            "organization": {
                "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant",
            "officialTitle": "Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant",
            "therapeuticArea": [
                "Other"
            ],
            "study": "multiple-myeloma-outcomes-based-on-maintenance-therapy-post-autologous-stem-cell-transplant"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-02-28",
            "studyFirstSubmitQcDate": "2022-02-28",
            "studyFirstPostDateStruct": {
                "date": "2022-03-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Adaptive Biotechnologies",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).",
            "detailedDescription": "This non-interventional, cohort prospective research study will assess outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post ASCT."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Minimal Residual Disease (MRD) testing by Clonoseq will be performed in the peripheral blood of the patients at the same time points that MRD testing will be done in the bone marrow in addition to at 6 and 18 months.\n\nInvestigators will examine the impact gut microbiota on MRD status and racial ethnic differences in study population. Stool samples will be collected at baseline and 1- and 2-years post Autologous Stem Cell Transplant."
            },
            "enrollmentInfo": {
                "count": 69,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single Maintenance After Autologous Stem Cell Transplant",
                    "description": "Prospectively enrolled cohort of patients receiving single maintenance therapy with an immunomodulatory drug after Autologous Stem Cell Transplant for Multiple Myeloma",
                    "interventionNames": [
                        "Other: Autologous Stem Cell Transplant",
                        "Drug: Immunomodulatory Agent"
                    ]
                },
                {
                    "label": "Double Maintenance After Autologous Stem Cell Transplant",
                    "description": "Prospectively enrolled cohort of patients receiving double maintenance therapy with the combination of an immunomodulatory drug and a proteasome inhibitor after Autologous Stem Cell Transplant for Multiple Myeloma.",
                    "interventionNames": [
                        "Other: Autologous Stem Cell Transplant",
                        "Drug: Immunomodulatory Agent",
                        "Drug: Proteasome Inhibitor"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Autologous Stem Cell Transplant",
                    "description": "This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT",
                    "armGroupLabels": [
                        "Double Maintenance After Autologous Stem Cell Transplant",
                        "Single Maintenance After Autologous Stem Cell Transplant"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Immunomodulatory Agent",
                    "description": "ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant",
                    "armGroupLabels": [
                        "Double Maintenance After Autologous Stem Cell Transplant",
                        "Single Maintenance After Autologous Stem Cell Transplant"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Proteasome Inhibitor",
                    "description": "ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant",
                    "armGroupLabels": [
                        "Double Maintenance After Autologous Stem Cell Transplant"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "MRD conversion rate",
                    "description": "To determine rate of MRD conversion (positive to negative) in MM patients receiving an immunomodulatory drug in combination with a proteasome inhibitor as maintenance therapy 1-year post transplant.",
                    "timeFrame": "At 1 year after transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression Free Survival (PFS) at 1 Year",
                    "description": "PFS is defined as time from transplant to disease progression, death or last follow-up date, whichever comes first. PFS will be estimated by Kaplan-Meier method and 95% confidence interval",
                    "timeFrame": "At 1 Years"
                },
                {
                    "measure": "Progression Free Survival (PFS) at 2 Years",
                    "description": "PFS is defined as time from transplant to disease progression, death or last follow-up date, whichever comes first. PFS will be estimated by Kaplan-Meier method and 95% confidence interval",
                    "timeFrame": "At 2 years"
                },
                {
                    "measure": "MRD by NGS Clonoseq testing",
                    "description": "MRD testing by NGS Clonoseq in peripheral blood of participants and correlate with same testing in bone marrow",
                    "timeFrame": "At 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* All MM patients (18 years or greater) receiving autologous transplantation given as first line therapy (Melphalan at least 140 mg/m2) will be screened and enrolled in the study if they qualify and willing to participate.\n* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Histologically confirmed diagnosis of multiple myeloma.\n* Received high dose melphalan (\u2265 140 mg/m2) followed by ASCT based on the institutional guidelines and within +60 and +180 after ASCT at the time of maintenance initiation.\n* Disease status must be very good partial response (VGPR), complete remission (CR), or stringent complete remission (sCR) per IMWG response criteria at time of study entry.\n* Measurable disease at diagnosis per IMWG criteria serum M spike \u2265 1g/dL, or Urine M protein \u2265 200 mg/24h or involved free light chain \u2265 100 mg/L with an abnormal ratio.\n* Patients must have the Clonoseq ID sample showing a trackable clone in bone marrow.\n\nExclusion Criteria:\n\n* Patients who have purely non-secretory multiple myeloma (i.e., the absence of a measurable protein in serum by electrophoresis and immunofixation and the absence of Bence-Jones protein in the urine defined by use of electrophoresis and immunofixation)\n* Prior evidence of disease progression\n* Patients who have other malignancy associated with a high risk of progression in the next 2 years.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Multiple Myeloma patients receiving treatment at Moffitt Cancer Center",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Garrett Welch",
                    "role": "CONTACT",
                    "phone": "813-745-6514",
                    "email": "Garrett.Welch@moffitt.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Doris Hansen, MD",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Garret Welch",
                            "role": "CONTACT",
                            "phone": "813-745-6514",
                            "email": "Garret.Welch@moffitt.org"
                        },
                        {
                            "name": "Doris Hansen, MD",
                            "role": "CONTACT",
                            "phone": "813-745-6162",
                            "email": "Doris.Hansen@moffitt.org"
                        },
                        {
                            "name": "Melissa Alsina, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Rachid Baz, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Brandon Blue, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jason Brayer, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Hien D Liu, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jose Ochoa, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Taiga Nishihori, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ken Shain, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Omar Castaneda, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ciara Freeman, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Moffitt Clinical Trial Search",
                    "url": "https://moffitt.org/clinical-trials-research/clinical-trials/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000061988",
                    "term": "Proteasome Inhibitors"
                },
                {
                    "id": "D000091369",
                    "term": "Immunomodulating Agents"
                }
            ],
            "ancestors": [
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "asFound": "Maltitol",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29889",
                    "name": "Proteasome Inhibitors",
                    "asFound": "Measured from",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}